Patients received Treatments ( A ) placebo/placebo , ( B ) canagliflozin 300 mg/placebo , ( C ) canagliflozin 300 mg/canagliflozin 300 mg , or ( D ) canagliflozin 300 mg/canagliflozin 150 mg on Day 2/Day 3 in one of four treatment sequences ( similar urinary glucose excretion [ UGE ] expected for Treatments B-D ) .